Revvity, Inc.
158.77USD
+1.4800 (+0.94%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on RVTY.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Price
Reading the stored fundamentals…
Dated 52-week rows are the highest and lowest CLOSE and the day each happened, which sits a little inside the intraday range a vendor quotes. Quotes are refreshed once a night — during a session the price above is the previous close.
Is the price low against peers, cash flow and analyst targets?
Do analysts expect earnings and revenue to keep growing?
1 of 6 checks could not be assessed (there is no analyst coverage stored).
Has the business grown and earned good returns on its filed numbers?
Can the balance sheet carry its debt?
Is the dividend decent, covered and steady?
Only 3 of 6 checks could be assessed because there is not enough stored history; 4 are needed.
An axis marked n/a has no vertex: it is left out of the shape rather than drawn as zero.
Each axis asks six plain questions of the stored data. A check that passes counts one. A check the stored data cannot answer is left out of the count, never counted as a fail, and an axis needs four answerable checks to show a result. Axes are never added together: there is no overall score. The thresholds are conventional rules of thumb and are blunt across sectors, so each check is listed with its rule and the figure it used.
P/E below peers
Trailing P/E is positive and below the median of its peers: the companies in its industry if there are at least 5, else its sector if at least 10, else the whole market if at least 30, always in the same currency.
P/E 76.0 against a peer median of 35.5 (13 USD companies in Diagnostics & Research).
Did not pass
PEG ratio
The PEG ratio is positive and at most 1.5.
PEG 0.73.
Passed
EV/EBITDA below peers
EV/EBITDA is positive and below the peer median, with peers chosen as for P/E. Not applied to financial companies.
EV/EBITDA 22.9 against a peer median of 27.8 (15 USD companies in Diagnostics & Research).
Passed
Price/book below peers
Price to book is positive and below the peer median, with peers chosen as for P/E.
Price/book 2.45 against a peer median of 5.80 (17 USD companies in Diagnostics & Research).
Passed
Statements: SEC filings, newest period 07/2026.
Peers: P/E against 13 USD companies in Diagnostics & Research; EV/EBITDA against 15 USD companies in Diagnostics & Research; price/book against 17 USD companies in Diagnostics & Research.
Rules of thumb applied to stored filings and quote data. Statements are as of the newest period shown above; multiples, analyst targets, estimates and yield come from a best-effort refresh and can lag by days. A count of plain checks, not a rating, a valuation or investment advice. Terms
Free cash flow yield
Free cash flow is at least 4.5% of market cap, the risk-free rate used across this site. Not applied to financial companies.
Free cash flow yield 3.2% against a 4.5% risk-free rate.
Did not pass
Analyst target above price
The mean analyst target is at least 15% above the last close, from at least 3 analysts. A published consensus, not a fair value.
Mean analyst target below the last close by 7.1% (15 analysts).
Did not pass
Earnings growth, next year
Consensus EPS for next fiscal year is at least 10% above this year's consensus, from at least 3 analysts.
Next year's EPS: consensus up 10.2% (17 analysts).
Passed
Earnings growth, this year
Consensus EPS for this fiscal year is at least 10% above last year's figure on the same street basis, from at least 3 analysts.
This year's EPS: consensus up 5.8% (17 analysts).
Did not pass
Revenue growth, next year
Consensus revenue for next fiscal year is at least 5% above this year's consensus, from at least 3 analysts.
Next year's revenue: consensus up 5.4% (16 analysts).
Passed
Revenue growth, this year
Consensus revenue for this fiscal year is at least 5% above last year's reported revenue, from at least 3 analysts.
This year's revenue: consensus down 0.1% (16 analysts).
Did not pass
Estimates rising
More analysts raised than cut this year's EPS estimate over the last 90 days, with at least 2 revisions in all.
No analyst estimates are stored for this security.
Not assessed
Revenue growth, latest quarter
Revenue in the latest quarter is at least 8% above the same quarter a year earlier.
Latest-quarter revenue up 1.3% on a year earlier.
Did not pass
Earnings growth, multi-year
Net income grew at least 5% a year over up to 5 fiscal years (at least 3 annual figures, positive at both ends).
Net income fell 41.0% a year, FY2023 to FY2025.
Did not pass
Earnings growth, last year
Net income over the latest twelve months is above the twelve months before it, and positive.
Net income down 16.7% (twelve months to 07/2026).
Did not pass
Revenue growth, multi-year
Revenue grew at least 3% a year over up to 5 fiscal years (at least 3 annual figures).
Revenue grew 1.9% a year, FY2023 to FY2025.
Did not pass
Return on equity
Return on equity is at least 15%: twelve-month net income over average equity. Not meaningful when equity is negative.
Return on equity 3.2%: twelve-month net income over the average equity.
Did not pass
Return on assets
Return on assets is at least 5%: twelve-month net income over average assets. Not applied to financial companies.
Return on assets 1.9%: twelve-month net income over the average assets.
Did not pass
Cash earnings
Operating cash flow over the latest twelve months is positive and at least net income. Not applied to financial companies.
Operating cash flow was at or above net income over the last twelve months.
Passed
Current ratio
Current assets are at least 1.0x current liabilities. Not applied to financial companies.
Current ratio 1.8x.
Passed
Short-term assets cover long-term liabilities
Current assets are at least the liabilities that fall due after a year (total liabilities less current liabilities). Not applied to financial companies.
Current assets are 0.6x the liabilities due after a year.
Did not pass
Debt to equity
Total debt is at most 100% of equity; no debt passes, negative equity with debt does not. Not applied to financial companies.
Total debt is 44% of equity.
Passed
Net debt to EBITDA
Net debt (total debt less cash) is at most 3.0x EBITDA; a net cash position passes. Not applied to financial companies.
Net debt is 3.6x EBITDA.
Did not pass
Interest cover
Operating income covers interest expense at least 3.0x; no debt passes. Not applied to financial companies.
Operating income covers interest 3.8x.
Passed
Cash flow to debt
Operating cash flow is at least 20% of total debt; no debt passes. Not applied to financial companies.
Operating cash flow is 19.6% of total debt.
Did not pass
Dividend yield
The dividend yield is at least 2%.
Dividend yield 0.18%.
Did not pass
Payout ratio
Dividends paid are at most 75% of net income. Not applied to real estate companies, whose net income is after depreciation.
Dividends paid were 13% of net income.
Passed
Free cash flow cover
Free cash flow covers the dividends paid at least 1.0x. Not applied to financial companies.
Free cash flow covers dividends 17.6x.
Passed
Paid every year
A dividend was paid in every one of the last 4 to 8 fiscal years stored (consecutive years, all present). A year missing from the filings data is not read as no dividend, so a gap makes this not assessed.
3 consecutive fiscal years are stored; 4 are needed.
Not assessed
No cuts
Total dividends paid never fell by more than 20% from one fiscal year to the next in that window.
3 consecutive fiscal years are stored; 4 are needed.
Not assessed
Growing dividend
Total dividends paid grew at least 3% a year across that window. The total, not per share: no per-share dividend history is stored.
3 consecutive fiscal years are stored; 4 are needed.
Not assessed